Benaroya Research Institute At Virginia Mason

Benaroya Research Institute At Virginia Mason, a non-profit biomedical research institute and subsidiary of Virginia Mason Health System headquartered in Seattle, Washington, operates as a prime recipient on federal research grants focused on immunology, autoimmune disease, and infectious disease mechanisms, with a secondary role as a grant sub-recipient to academic prime institutions. The institute competes predominantly in full-and-open federal research funding—principally through the National Institutes of Health's grant mechanisms—rather than under set-aside categories.

Benaroya's federal footprint centers on investigator-initiated biomedical research services. Recent representative prime grant work includes a $886,942 National Institute of Allergy and Infectious Diseases (NIAID) project award (CFDA 93.855) on commensal-specific CD8+ T cell differentiation in intestinal inflammation (completion May 2031); a $2.68 million NIAID award on epitope-specific CD4+ T cell responses in Type 1 Diabetes (completion January 2030); a $1.385 million NIAID award on CD4+ tissue resident memory T cells in experimental autoimmune encephalomyelitis as a model of multiple sclerosis (completion June 2030); and a $1.559 million NIH Office of the Director Trans-NIH Research Support award on genetic and epigenetic control of T cell function in autoimmunity (completion August 2026). The institute's research agenda spans Type 1 Diabetes, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, asthma, Down syndrome immunology, and vaccine response in vulnerable populations. Work involves single-cell transcriptomics, immunological characterization, T cell and B cell phenotyping, gene expression analysis, CRISPR screening, epigenetic profiling, and longitudinal cohort studies.

The National Institute of Allergy and Infectious Diseases dominates customer concentration, accounting for 86 awards with $5.4 million in combined potential value across the recent award portfolio. The broader NIH ecosystem—including the National Institute of Diabetes and Digestive and Kidney Diseases (39 awards), the National Heart, Lung, and Blood Institute (12 awards), and the Office of the Director (9 awards)—represents the near-totality of Benaroya's federal funding. A single Department of Health and Human Services Acquisitions contract vehicle carries $16.7 million in potential value across three task orders, the largest single concentration point in the portfolio.

Activity has expanded year over year, from 11 prime and sub awards in 2022 to 33 in 2024 and 32 in 2025 (10 recorded through July 2026). Seventeen awards carry ultimate completion dates within the next twenty-four months and face recompete or closeout. Across SCI-reportable service contracts captured above the $150,000 threshold, Benaroya invoiced $1.2 million in FY2022 across 3.7 FTEs at a median government-paid rate of $142.04 per hour; SCI records show no invoiced revenue in FY2023 or FY2024, reflecting the institute's primary focus on grant-funded research rather than time-and-materials service contracting.

Benaroya operates predominantly as a prime grant recipient (74% of awards) with a secondary sub-recipient footprint (26% of awards). Recent sub-recipient work includes collaborations with Yale University on CD4+ T cell neoepitope responses in Type 1 Diabetes, with the University of South Florida on environmental determinants of diabetes and Type 1 Diabetes TrialNet data coordination, with the Jackson Laboratory on lung immune responses to respiratory viral infection, with the University of Washington on epithelial immune responses in asthma exacerbation and machine learning vaccine design, and with the La Jolla Institute for Immunology on HIPC bioinformatics leadership roles. The institute also serves as a sub-recipient under grants from Oregon Health & Science University (SWOG network operations), Indiana University (T cell clone and HLA tetramer work), and Stanford University (pulmonary edema and ARDS studies). Across SCI-reportable prime contracts, sub-hours represent 2% of total contractor hours, indicating that Benaroya builds most delivery capability internally rather than through deep subcontracting networks.

The institute maintains substantial biorepositories and longitudinal cohort access—particularly in Type 1 Diabetes, rheumatoid arthritis, systemic lupus erythematosus, Down syndrome, and respiratory disease—which serve as a competitive asset attracting collaborative grant leadership roles and sub-recipient assignments from larger academic institutions. The facility's immunological characterization and multi-omics capabilities (single-cell RNA sequencing, CyTOF, spatial transcriptomics, epigenetic profiling, tetramer-based T cell isolation) position it as a research services core and co-investigator resource for consortium-scale investigations in autoimmune disease and vaccine response.